1. In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative, node-positive, early breast cancer at high risk of recurrence.
2. In combination with an aromatase inhibitor for the initial endocrine-based therapy of adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer.
3. In combination with fulvestrant for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
